Nidanilimab

• CAT Number: I042218
• CAS Number: 2171061-85-9
• Purity: ≥95%

Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2].
Nidanilimab (CAN04; 20 µg/mL; murine MC38 colon cancer cells) has glycoengineered to mediate an enhanced antibody-dependent cellular cytotoxicity (ADCC, EC50<1 nM)[2]. Nidanilimab (20 µg/mL; murine MC38 colon cancer cells) blocks IL1α and IL1β signaling with IC50 values of 3.9 nM and 4.1 nM, respectively.
Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies[1].

Reference

[1]. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.

[2]. Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.
 [Content Brief]